Journal of Hepatology Hepatology

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →